Apply to trial NCT06029309

A few quick questions so the study team can decide if you might be a fit.

RecruitingDrug trial

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the study disease.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening